IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung Cancer

Clinical trial NCT07408635 · RECRUITING

Trial details

NCT number: NCT07408635
Sponsor: Shanghai Pulmonary Hospital, Shanghai, China
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Unresectable Stage III Non-small Cell Lung Cancer Carcinoma, Non-Small-Cell Lung Cancer (NSCLC)

Start date: 2026-01-07
Primary completion: 2028-06-06
Enrollment: 43

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.